Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.45 |
| ▸ | JAK1 | P23458 | 5/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133672 | 0.95 | ADORA1 (0.47) | LMNAADORA1ADORA2AJAK1ADORA3 | |
| SCHEMBL6133749 | 0.87 | TP53 (0.44) | LMNAADORA1ADORA3 | |
| SCHEMBL6134592 | 0.86 | ADORA1 (0.47) | LMNAADORA1ADORA2AADORA3 | |
| SCHEMBL6134310 | 0.85 | GAA (0.45) | ADORA1ADORA2AADORA3 | |
| SCHEMBL6134405 | 0.85 | KDM4E (0.40) | LMNAADORA1ADORA2AJAK2 | |
| SCHEMBL6135441 | 0.85 | POLB (0.47) | LMNAADORA1 | |
| SCHEMBL6134588 | 0.84 | ADORA1 (0.48) | ADORA1ADORA2AADORA3 | |
| SCHEMBL6134095 | 0.83 | ADORA1 (0.57) | ADORA1ADORA2AADORA3 | |
| SCHEMBL6135183 | 0.83 | MERTK (0.42) | ADORA1ADORA2A | |
| SCHEMBL6134129 | 0.82 | ADORA2A (0.48) | LMNAADORA1ADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | LMNA 3549/4885ADORA1 3/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.